Benefits Plans - Prescription Drug Plan: Drug Plan Updates and New Drug Releases - Drug Reviews

Page last updated: Wednesday, 26-May-2010 20:51:26 EDT

The following drug considerations were reviewed and determined for formulary inclusion and tier placement by the U-M Pharmaceutical Benefits Advisory Committee in January through March, 2006.

Drug Name Indication PDL Class
Yes/No
Action
Derm Otic Otic Eczema No Tier 3
Nevanac 0.1% O.S. Eye Anti-inflammatory No Tier 3
Xibrom 0.09% Eye Anti-inflammatory No Tier 2
Avandaryl Hypoglycemic Yes Tier 3
Nexavar Antineoplastic No Tier 2
Exjade Iron overload No Tier 2
Sutent Antineoplastic No Tier 2
Revlimid MDS Anemia No Tier 2
Levemir Hypoglycemic No $0 co-pay, Insulin
Limitations
The University of Michigan in its sole discretion may modify, amend, or terminate the benefits provided with respect to any individual receiving benefits, including active employees, retirees, and their dependents. Although the university has elected to provide these benefits this year, no individual has a vested right to any of the benefits provided. Nothing in these materials gives any individual the right to continued benefits beyond the time the university modifies, amends, or terminates the benefit. Anyone seeking or accepting any of the benefits provided will be deemed to have accepted the terms of the benefits programs and the university's right to modify, amend or terminate them.